<DOC>
	<DOCNO>NCT01144442</DOCNO>
	<brief_summary>This open-label , pilot study patient diagnosis recurrent ovarian , fallopian tube primary peritoneal carcinoma undergone standard cytoreductive surgery follow adjuvant chemotherapy . It expect first surgery optimal - define residual tumor &gt; = 1 centimeter . Patient clinical evidence first recurrence . The patient undergo surgery isotonic normal saline ( perfusate ) heat administered abdomen , follow hyperthermic intraperitoneal chemotherapy infusion ( HIPC ) administer carboplatin ( chemotherapy ) . Six week surgery patient receive adjuvant chemotherapy Paclitaxel Carboplatin 6 cycle .</brief_summary>
	<brief_title>WCC # 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin First Recurrence Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES - The primary objective - determine clinical response hyperthermic intraperitoneal chemotherapy ( HIPC ) patient time first clinical recurrence ovarian , fallopian tube , primary peritoneal carcinoma - determine feasibility deliver HIPC recurrent set . - Secondary objective - determine disease free survival ( DFS ) overall survival ( OS ) , - determine treatment relate change quality life ( QOL ) - monitor toxicity complication associate HIPC .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histological diagnosis primary ovarian , fallopian tube , primary peritoneal carcinoma undergone chemotherapy accord . Initial attempt cytoreductive surgery must perform gynecologic oncologist strict adherence GOG surgical manual . End result first surgery must optimal cytoreduction define residual tumor ≥ 1cm . Patients clinical evidence first recurrence . Two fold elevation CA125 measurable tumor CT scan constitute adequate evidence recurrent disease . Patients follow primary tumor epithelial cell type eligible : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , adenocarcinoma ( nonspecific ) NOS , mixed epithelial carcinoma . Patients must platin sensitive disease , define recurrence occur great 6 month cessation original treatment . Patients must performance status 0 , 1 , 2 . Patients must adequate bone marrow function define absolute neutrophil count ( ANC ) ≥1500 , platelet count ≥ 100,000 , hemoglobin great 10g/dl . Patients must adequate renal function define serum creatinine ≤ 1.5 mg/dl . Patients must adequate hepatic function define bilirubin ≤ 1.5 time normal level , alkaline phosphatase SGOT ≤ 3 time normal level . Patients sign Institutional Review Board ( IRB ) approve informed consent . Female patient 1690 year age . Patients must deem medically able undergo secondary surgical procedure . Patient eligibility systemic chemotherapy follow HIPC : Patients must successfully complete HIPC within 6 week first prescribe intravenous carboplatin taxane cycle . Patients must performance status 0 , 1 , 2 . Patients must adequate bone marrow function define ANC ≥ 1500 , platelet count ≥ 100,000 , hemoglobin great 10g/dl . Patients must adequate renal function define serum creatinine ≤ 1.5 mg/dl . Patients must adequate hepatic function define bilirubin ≤ 1.5 time normal level , alkaline phosphatase SGOT ≤ 3 time normal level . Patients sign IRB approve informed consent . Patients know recurrent disease outside abdominal cavity . Patients low malignant tumor primary diagnosis determine pathologic review . Patients platin resistant disease define recurrence progressive disease prior 6 month completion primary therapy . Patients evidence another malignancy within last 5 year exception nonmelanoma skin cancer . Patients evidence concurrent septicemia , severe infection , renal failure , acute hepatitis . Patients history grade 3 great gastrointestinal bleeding . Patients GOG performance score 3 4 . Patients deem medically unable tolerate HIPC procedure care give physician . Patients know allergy platinum chemotherapy agent . Patients equal great grade 2 neuropathy .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>recurrent peritoneal carcinoma</keyword>
</DOC>